Recent Updates
Recently added Catalysts
BIIB Positive Sentiment

Biogen to Participate in the Wells Fargo 21st Annual Healthcare Conference

Tuesday, August 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Biogen Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference, featuring a fireside chat with CFO Robin Kramer and Head of Corporate Development Adam Keeney. The event aims to enhance investor relations and provide insights into the company's strategies. The webcast is scheduled for September 9.

Market Sentiment Analysis

POSITIVE FACTORS

  • Biogen's participation highlights its engagement with investors.
  • The event provides a platform for discussing future strategies.
  • Key executives will be present to share insights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis

Full Press Release Details

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Robin Kramer, Chief Financial Officer, and Adam Keeney, Head of Corporate Development, will participate in a fireside chat during the Wells Fargo 21st Annual Healthcare Conference. The webcast will be live on Wednesday, Sept 9,

Frequently Asked Questions

Who will represent Biogen at the conference?

Robin Kramer and Adam Keeney will represent Biogen.

When is the Wells Fargo Healthcare Conference?

The conference is scheduled for September 9.

What type of event is the Wells Fargo conference?

It features a fireside chat format for discussions.

What is the purpose of Biogen's participation?

To enhance investor relations and share company insights.

ShareAdd on Google
Tags: BIIB Viatris Investor Conferences Healthcare Biogen Wells Fargo Healthcare Conference Robin Kramer Adam Keeney
Last updated: Aug 25, 2026

Biotech snapshot

Cash runway
$3878M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AlefaceptPhase 3
Chronic Plaque Psoriasis →

Catalyst track record

+34%
best trade around BIIB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for BIIB.

See every catalyst's timing & PoA →